# US 2024/0197689 A1 · Thiazolidinedione analogs for the treatment of nafld and metabolic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197689 A1
- Document ID: US20240197689A1
- Status: Published application
- Kind: A1
- Application number: 18/435,285
- Filed: 2024-02-07
- Published: 2024-06-20
- Earliest claimed: 2018-05-04
- Assignees: Cirius Therapeutics, Inc.
- Applicants: Cirius Therapeutics, Inc.
- Inventors: Gerard R. Colca
- Web page: https://patentgrep.com/patent/US20240197689A1

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61K 38/26: Glucagons
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07D 277/34: Oxygen atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders.

## Claims

### Claim 1

A method of treating non-alcoholic fatty liver disease (NAFLD) and/or metabolic syndrome, comprising administering to a subject in need thereof:
(i) a therapeutically effective amount of a compound of structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR1A;
R2 is halogen, hydroxyl, or optionally substituted aliphatic;
R2′ is hydrogen, or R2 and R2′ may optionally be joined to form oxo;
R3 is hydrogen or deuterium;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR4A;
A is phenyl; and
R1A and R4A are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, CI3, —CHF2, —CHCl2, —CHBr2, —CHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
(ii) at least one additional therapeutic agent selected from a GLP1 agonist, a phosphodiesterase (PDE) inhibitor, and a thyroid hormone beta receptor agonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein R3 is hydrogen.

### Claim 3 (depends on 2)

The method of claim 2, wherein R4 is:
hydrogen, methyl, or —OR4A; and
R4A is methyl, ethyl, isopropyl, —CHF2, or —CF3.

### Claim 4 (depends on 3)

The method of claim 3, wherein R4 is hydrogen.

### Claim 5 (depends on 1)

The method of claim 1, wherein R1 is:
hydrogen, halogen, or —OR1A; and
R1A is substituted or unsubstituted alkyl.

### Claim 6 (depends on 5)

The method of claim 5, wherein R1 is hydrogen.

### Claim 7 (depends on 5)

The method of claim 5, wherein R1 is halogen.

### Claim 8 (depends on 5)

The method of claim 5, wherein R1 is —OR1A and R1A is substituted or unsubstituted alkyl.

### Claim 9 (depends on 7)

The method of claim 7, wherein R1 is attached to the para or meta position of the phenyl.

### Claim 10 (depends on 7)

The method of claim 7, wherein R1 is attached to the meta position of the phenyl.

### Claim 11 (depends on 9)

The method of claim 9, wherein R1 is —F or —Cl.

### Claim 12 (depends on 8)

The method of claim 8, wherein R1 is attached to the ortho or meta position of the phenyl.

### Claim 13 (depends on 8)

The method of claim 8, wherein R1 is attached to the meta position of the phenyl.

### Claim 14 (depends on 12)

The method of claim 12, wherein R1A is substituted or unsubstituted C1-C3alkyl.

### Claim 15 (depends on 14)

The method of claim 14, wherein R1A is —CHF2 or —CF3.

### Claim 16 (depends on 1)

The method of claim 1, wherein R2 is hydrogen.

### Claim 17 (depends on 16)

The method of claim 16, wherein R2 is hydroxyl.

### Claim 18 (depends on 1)

The method of claim 1, wherein R2 and R2′ are joined to form oxo.

### Claim 19 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

The method of claim 1, wherein the GLP1 agonist is exenatide, liraglutide, semaglutide, or dulaglutide.

### Claim 22 (depends on 21)

The method of claim 21, wherein the GLP1 agonist is exenatide.

### Claim 23 (depends on 1)

The method of claim 1, wherein the PDE inhibitor is a PDE4 and/or a PDE5 inhibitor.

### Claim 24 (depends on 1)

The method of claim 1, wherein the PDE inhibitor is pentoxifylline, theophylline, ibudilast, roflumilast, sildenafil, or tadalafil.

### Claim 25 (depends on 1)

The method of claim 1, wherein the thyroid hormone beta receptor agonist is MGL-3196, VK2809, or VK0214.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered orally.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is formulated as a tablet or capsule.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in a dose of from about 60 mg to about 250 mg.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered daily.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered once daily.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the GLP1 agonist is administered orally, by injection, or by an implantable mini-pump.

### Claim 32 (depends on 31)

The method of claim 31, wherein the GLP1 agonist is administered by an implantable mini-pump.

### Claim 33 (depends on 31, 32)

The method of claim 31 or 32, wherein the implantable mini-pump is a 6-month pump.

### Claim 34 (depends on 31, 32, 33)

The method of any one of claims 31-33, wherein a single implantable mini-pump is used.

### Claim 35 (depends on 31)

The method of claim 31, wherein the GLP1 agonist is administered by injection.

### Claim 36 (depends on 31, 35)

The method of claim 31 or 35, wherein the GLP1 agonist is injected approximately once monthly.

### Claim 37 (depends on 36)

The method of claim 36, wherein the GLP1 agonist is injected for a period of up to about 6 months.

### Claim 38 (depends on 31, 35)

The method of claim 31 or 35, wherein the GLP1 agonist is injected approximately once weekly.

### Claim 39 (depends on 38)

The method of claim 38, wherein the GLP1 agonist is injected approximately once weekly for a period of up to about 25 weeks.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the PDE inhibitor is administered orally.

### Claim 41 (depends on 40)

The method of claim 40, wherein the PDE inhibitor is administered for a period of up to about 6 months.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1-41, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the at least one additional therapeutic agent are administered simultaneously, approximately simultaneously, or sequentially, in any order.

### Claim 43 (depends on 42)

The method of claim 42, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the at least one additional therapeutic agent are administered simultaneously or approximately simultaneously.

### Claim 44 (depends on 42)

The method of claim 42, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the at least one additional therapeutic agent are administered sequentially.

### Claim 45 (depends on 44)

The method of claim 44, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered before the at least one additional therapeutic agent.

### Claim 46 (depends on 44)

The method of claim 44, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered after the at least one additional therapeutic agent.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1-31 or 40-46, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is co-formulated with the at least one additional therapeutic agent.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the NAFLD is non-alcoholic steatohepatitis (NASH).

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 1-48, further wherein the subject has at least one metabolic inflammation-mediated disease or disorder.

### Claim 50 (depends on 49)

The method of claim 49, wherein the at least one metabolic inflammation-mediated disease or disorder is diabetes mellitus type 2.

### Claim 51

A method of treating non-alcoholic fatty liver disease (NAFLD) and/or at least one metabolic inflammation-mediated disease or disorder, comprising administering to a subject in need thereof:
(i) a therapeutically effective amount of a compound of structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR1A;
R2 is halogen, hydroxyl, or optionally substituted aliphatic;
R2′ is hydrogen, or R2 and R2′ may optionally be joined to form oxo;
R3 is hydrogen or deuterium;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR4A;
A is phenyl; and
R1A and R4A are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, —CI3, —CHF2, —CHCl2, —CHBr2, —CHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
(ii) at least one additional therapeutic agent selected from a phosphodiesterase (PDE) inhibitor, a thyroid hormone beta receptor agonist, or a GLP1 agonist.

### Claim 52 (depends on 51)

The method of claim 51, wherein the GLP1 agonist is liraglutide, semaglutide, or dulaglutide.

### Claim 53 (depends on 52)

The method of claim 52, wherein R3 is hydrogen.

### Claim 54 (depends on 53)

The method of claim 53, wherein R4 is:
hydrogen, methyl, or —OR4A; and
R4A is methyl, ethyl, isopropyl, —CHF2, or —CF3.

### Claim 55 (depends on 54)

The method of claim 54, wherein R4 is hydrogen.

### Claim 56 (depends on 52)

The method of claim 52, wherein R1 is:
hydrogen, halogen, or —OR1A; and
R1A is substituted or unsubstituted alkyl.

### Claim 57 (depends on 56)

The method of claim 56, wherein R1 is hydrogen.

### Claim 58 (depends on 56)

The method of claim 56, wherein R1 is halogen.

### Claim 59 (depends on 56)

The method of claim 56, wherein R1 is —OR1A and R1A is substituted or unsubstituted alkyl.

### Claim 60 (depends on 58)

The method of claim 58, wherein R1 is attached to the para or meta position of the phenyl.

### Claim 61 (depends on 58)

The method of claim 58, wherein R1 is attached to the meta position of the phenyl.

### Claim 62 (depends on 60)

The method of claim 60, wherein R1 is —F or —Cl.

### Claim 63 (depends on 59)

The method of claim 59, wherein R1 is attached to the ortho or meta position of the phenyl.

### Claim 64 (depends on 59)

The method of claim 59, wherein R1 is attached to the meta position of the phenyl.

### Claim 65 (depends on 63)

The method of claim 63, wherein RIA is substituted or unsubstituted C1-C3alkyl.

### Claim 66 (depends on 65)

The method of claim 65, wherein R1A is —CHF2 or —CF3.

### Claim 67 (depends on 52)

The method of claim 52, wherein R2′ is hydrogen.

### Claim 68 (depends on 67)

The method of claim 67, wherein R2 is hydroxyl.

### Claim 69 (depends on 52)

The method of claim 52, wherein R2 and R2′ are joined to form oxo.

### Claim 70 (depends on 52)

The method of claim 52, wherein the compound of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 71 (depends on 52)

The method of claim 52, wherein the compound of Formula (T) is:
or a pharmaceutically acceptable salt thereof.

### Claim 72 (depends on 52)

The method of claim 52, wherein the PDE inhibitor is a PDE4 and/or a PDE5 inhibitor.

### Claim 73 (depends on 52)

The method of claim 52, wherein the PDE inhibitor is pentoxifylline, theophylline, ibudilast, roflumilast, sildenafil, or tadalafil.

### Claim 74 (depends on 52)

The method of claim 52, wherein the thyroid hormone beta receptor agonist is MGL-3196, VK2809, or VK0214.

### Claim 75 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 52-74, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered orally.

### Claim 76 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 52-75, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is formulated as a tablet or capsule.

### Claim 77 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 52-76, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in a dose of from about 60 mg to about 250 mg.

### Claim 78 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 52-77, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered daily.

### Claim 79 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 52-78, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered once daily.

### Claim 80 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 52-79, wherein the PDE inhibitor is administered orally.

### Claim 81 (depends on 80)

The method of claim 80, wherein the PDE inhibitor is administered for a period of up to about 6 months.

### Claim 82 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 52-81, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the at least one additional therapeutic agent are administered simultaneously, approximately simultaneously, or sequentially in any order.

### Claim 83 (depends on 82)

The method of claim 82, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the at least one additional therapeutic agent are administered simultaneously or approximately simultaneously.

### Claim 84 (depends on 82)

The method of claim 82, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the at least one additional therapeutic agent are administered sequentially.

### Claim 85 (depends on 84)

The method of claim 84, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered before the at least one additional therapeutic agent.

### Claim 86 (depends on 84)

The method of claim 84, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered after the at least one additional therapeutic agent.

### Claim 87 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 52-83, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is co-formulated with the at least one additional therapeutic agent.

### Claim 88 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method of any one of claims 52-87, wherein the NAFLD is non-alcoholic steatohepatitis (NASH).

### Claim 89 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The method of any one of claims 52-88, wherein the subject has diabetes mellitus, NAFLD, or metabolic syndrome, or any combination thereof.

### Claim 90 (depends on 89)

The method of claim 89, wherein the diabetes mellitus is type 2.

### Claim 91

A method of treating non-alcoholic fatty liver disease (NAFLD) and/or metabolic syndrome, comprising administering to a subject in need thereof:
(i) a therapeutically effective amount of a pharmaceutical composition, comprising a compound of structural Formula (I):
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein:
R1 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR1A;
R2 is halogen, hydroxyl, or optionally substituted aliphatic;
R2′ is hydrogen, or R2 and R2′ may optionally be joined to form oxo;
R3 is hydrogen or deuterium;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR4A;
A is phenyl; and
R1A and R4A are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, —CI3, —CHF2, —CHCl2, —CHBr2, —CHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
(ii) at least one additional therapeutic agent selected from a GLP1 agonist, a phosphodiesterase (PDE) inhibitor, or a thyroid hormone beta receptor agonist.

### Claim 92

A method of treating non-alcoholic fatty liver disease (NAFLD) and/or at least one metabolic inflammation-mediated disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising:
i) a compound of structural Formula (I), or a pharmaceutically acceptable salt thereof:
wherein:
R1 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR1A;
R2 is halogen, hydroxyl, or optionally substituted aliphatic;
R2′ is hydrogen, or R2 and R2′ may optionally be joined to form oxo;
R3 is hydrogen or deuterium;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR4A;
A is phenyl; and
R1A and R4A are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, —CI3, —CHF2, —CHCl2, —CHBr2, —CHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
(ii) at least one additional therapeutic agent selected from a GLP1 agonist, a phosphodiesterase (PDE) inhibitor, or a thyroid hormone beta receptor agonist; and
(iii) and a pharmaceutically acceptable excipient, wherein the compound of Formula (I) and the at least one additional therapeutic agent selected from a GLP1 agonist, a phosphodiesterase (PDE) inhibitor, or a thyroid hormone beta receptor agonist are co-formulated.

### Claim 93 (depends on 91, 92)

The method of claim 91 or 92, wherein the compound of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The method of any one of claims 1-93, wherein the pharmaceutically acceptable salt is a potassium salt.

### Claim 95

A pharmaceutical composition, comprising a compound of structural formula:
or a pharmaceutically acceptable salt thereof, a GLP1 agonist and a pharmaceutically acceptable excipient.

### Claim 96 (depends on 95)

The pharmaceutical composition of claim 95, wherein the GLP1 agonist is exenatide, liraglutide, semaglutide, or dulaglutide.

### Claim 97 (depends on 95, 96)

The pharmaceutical composition of claim 95 or 96, wherein the pharmaceutically acceptable salt is a potassium salt.

### Claim 98 (depends on 95, 96, 97)

A method of treating non-alcoholic fatty liver disease (NAFLD) and/or metabolic syndrome, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of any one of claims 95-97.

### Claim 99

A method of treating at least one metabolic inflammation-mediated disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR1A;
R2 is halogen, hydroxyl, or optionally substituted aliphatic;
R2′ is hydrogen, or R2 and R2′ may optionally be joined to form oxo;
R3 is deuterium;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR4A;
A is phenyl; and
R1A and R4A are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, —CI3, —CHF2, —CHCl2, —CHBr2, —CHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 100 (depends on 99)

The method of claim 99, wherein R4 is:
hydrogen, methyl, or —OR4A; and
R4A is methyl, ethyl, isopropyl, —CHF2, or —CF3.

### Claim 101 (depends on 100)

The method of claim 100, wherein R4 is hydrogen.

### Claim 102 (depends on 99)

The method of claim 99, wherein R1 is:
hydrogen, halogen, or —OR1A; and
R1A is substituted or unsubstituted alkyl.

### Claim 103 (depends on 102)

The method of claim 102, wherein R1 is hydrogen.

### Claim 104 (depends on 102)

The method of claim 102, wherein R1 is halogen.

### Claim 105 (depends on 102)

The method of claim 102, wherein R1 is —OR1A and R1A is substituted or unsubstituted alkyl.

### Claim 106 (depends on 104)

The method of claim 104, wherein R1 is attached to the para or meta position of the phenyl.

### Claim 107 (depends on 104)

The method of claim 104, wherein R1 is attached to the meta position of the phenyl.

### Claim 108 (depends on 107)

The method of claim 107, wherein R1 is —F or —Cl.

### Claim 109 (depends on 105)

The method of claim 105, wherein R1 is attached to the ortho or meta position of the phenyl.

### Claim 110 (depends on 105)

The method of claim 105, wherein R1 is attached to the meta position of the phenyl.

### Claim 111 (depends on 105)

The method of claim 105, wherein R1A is substituted or unsubstituted C1-C3alkyl.

### Claim 112 (depends on 111)

The method of claim 111, wherein R1A is —CHF2 or —CF3.

### Claim 113 (depends on 99)

The method of claim 99, wherein R2′ is hydrogen.

### Claim 114 (depends on 113)

The method of claim 113, wherein R2 is hydroxyl.

### Claim 115 (depends on 99)

The method of claim 99, wherein R2 and R2′ are joined to form oxo.

### Claim 116 (depends on 99)

The method of claim 99, wherein the compound of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 117 (depends on 99)

The method of claim 99, wherein the at least one metabolic inflammation-mediated disease or disorder is diabetes mellitus.

### Claim 118 (depends on 117)

The method of claim 117, wherein the diabetes mellitus is type 2.

### Claim 119 (depends on 99)

The method of claim 99, wherein the subject has non-alcoholic fatty liver disease (NAFLD).

### Claim 120 (depends on 119)

The method of claim 119, wherein the NAFLD is non-alcoholic steatohepatitis (NASH).

### Claim 121 (depends on 99)

The method of claim 99, further comprising administering to the subject at least one additional therapeutic agent selected from a GLP1 agonist, a phosphodiesterase (PDE) inhibitor, or a thyroid hormone beta receptor agonist.

### Claim 122 (depends on 121)

The method of claim 121, wherein the PDE inhibitor is a PDE4 and/or a PDE5 inhibitor.

### Claim 123 (depends on 121)

The method of claim 121, wherein the PDE inhibitor is pentoxifylline, theophylline, ibudilast, roflumilast, sildenafil, or tadalafil.

### Claim 124 (depends on 121)

The method of claim 121, wherein the thyroid hormone beta receptor agonist is MGL-3196, VK2809, or VK0214.

### Claim 125 (depends on 121)

The method of claim 121, wherein the GLP1 agonist is exenatide, liraglutide, semaglutide, or dulaglutide.

### Claim 126

A method of inhibiting hepatic mitochondrial pyruvate carrier (MPC) in a cell, comprising contacting the MPU with a compound of structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR1A;
R2 is halogen, hydroxyl, or optionally substituted aliphatic;
R2′ is hydrogen, or R2 and R2′ may optionally be joined to form oxo;
R3 is hydrogen or deuterium;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR4A;
A is phenyl; and
R1A and R4A are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, —CI3, —CHF2, —CHCl2, —CHBr2, —CHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 127 (depends on 126)

The method of claim 126, wherein R3 is hydrogen.

### Claim 128 (depends on 127)

The method of claim 127, wherein R4 is:
hydrogen, methyl, or OR4A; and
R4A is methyl, ethyl, isopropyl, —CHF2, or —CF3.

### Claim 129 (depends on 128)

The method of claim 128, wherein R4 is hydrogen.

### Claim 130 (depends on 126)

The method of claim 126, wherein R1 is:
hydrogen, halogen or —OR1A; and
R1A is substituted or unsubstituted alkyl.

### Claim 131 (depends on 130)

The method of claim 130, wherein R1 is hydrogen.

### Claim 132 (depends on 130)

The method of claim 130, wherein R1 is halogen.

### Claim 133 (depends on 130)

The method of claim 130, wherein R1 is —OR1A and R1A is substituted or unsubstituted alkyl.

### Claim 134 (depends on 132)

The method of claim 132, wherein R1 is attached to the para or meta position of the phenyl.

### Claim 135 (depends on 132)

The method of claim 132, wherein R1 is attached to the meta position of the phenyl.

### Claim 136 (depends on 134)

The method of claim 134, wherein R1 is —F or —Cl.

### Claim 137 (depends on 133)

The method of claim 133, wherein R1 is attached to the ortho or meta position of the phenyl.

### Claim 138 (depends on 133)

The method of claim 133, wherein R1 is attached to the meta position of the phenyl.

### Claim 139 (depends on 137)

The method of claim 137, wherein R1A is substituted or unsubstituted C1-C3alkyl.

### Claim 140 (depends on 139)

The method of claim 139, wherein R1A is —CHF2 or —CF3.

### Claim 141 (depends on 126)

The method of claim 126, wherein R2′ is hydrogen.

### Claim 142 (depends on 141)

The method of claim 141, wherein R2 is hydroxyl.

### Claim 143 (depends on 126)

The method of claim 126, wherein R2 and R2′ are joined to form oxo.

### Claim 144 (depends on 126)

The method of claim 126, wherein the of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 145 (depends on 126)

The method of claim 126, wherein the compound of Formula (I) is:

### Claim 146 (depends on 126)

The method of claim 126, wherein the cell is a hepatocyte.

### Claim 147 (depends on 146)

The method of claim 146, wherein the hepatocyte is in vivo.

### Claim 148 (depends on 146)

The method of claim 146, wherein the hepatocyte is a human hepatocyte.

### Claim 149 (depends on 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148)

The method of any one of claims 126-148, wherein the pharmaceutically acceptable salt is a potassium salt.

### Claim 150

A method of improving or increasing glucose tolerance and/or insulin sensitivity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula (I)
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR1A;
R2 is halogen, hydroxyl, or optionally substituted aliphatic;
R2′ is hydrogen, or R2 and R2′ may optionally be joined to form oxo;
R3 is hydrogen or deuterium;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR4A;
A is phenyl; and
R1A and R4A are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, CI3, —CHF2, —CHCl2, —CHBr2, —CHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 151 (depends on 150)

The method of claim 150, wherein R3 is hydrogen.

### Claim 152 (depends on 151)

The method of claim 151, wherein R4 is:
hydrogen, methyl, or —OR4A; and
R4A is methyl, ethyl, isopropyl, —CHF2, or —CF3.

### Claim 153 (depends on 152)

The method of claim 152, wherein R4 is hydrogen.

### Claim 154 (depends on 151)

The method of claim 151, wherein R1 is:
hydrogen, halogen, or —OR1A; and
R1A is substituted or unsubstituted alkyl.

### Claim 155 (depends on 154)

The method of claim 154, wherein R1 is hydrogen.

### Claim 156 (depends on 154)

The method of claim 154, wherein R1 is halogen.

### Claim 157 (depends on 154)

The method of claim 154, wherein R1 is —OR1A and R1A is substituted or unsubstituted alkyl.

### Claim 158 (depends on 157)

The method of claim 157, wherein R1 is attached to the para or meta position of the phenyl.

### Claim 159 (depends on 157)

The method of claim 157, wherein R1 is attached to the meta position of the phenyl.

### Claim 160 (depends on 158)

The method of claim 158, wherein R1 is —F or —Cl.

### Claim 161 (depends on 157)

The method of claim 157, wherein R1 is attached to the ortho or meta position of the phenyl.

### Claim 162 (depends on 157)

The method of claim 157, wherein R1 is attached to the meta position of the phenyl.

### Claim 163 (depends on 161)

The method of claim 161, wherein R1A is substituted or unsubstituted C1-C3alkyl.

### Claim 164 (depends on 163)

The method of claim 163, wherein R1A is —CHF2 or —CF3.

### Claim 165 (depends on 150)

The method of claim 150, wherein R2′ is hydrogen.

### Claim 166 (depends on 165)

The method of claim 165, wherein R2 is hydroxyl.

### Claim 167 (depends on 150)

The method of claim 150, wherein R2 and R2′ are joined to form oxo.

### Claim 168 (depends on 150)

The method of claim 150, wherein the compound of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 169 (depends on 150)

The method of claim 150, wherein the compound of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 170 (depends on 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169)

The method of any one of claims 150-169, wherein the subject is suffering from obesity, non alcoholic fatty liver disease (NAFLD), a metabolic inflammation-mediated disease or disorder, metabolic syndrome, or any combination thereof.

### Claim 171 (depends on 170)

The method of claim 170, wherein the NAFLD is non-alcoholic steatohepatitis (NASH).

### Claim 172 (depends on 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171)

The method of any one of claims 150-171, wherein the pharmaceutically acceptable salt is a potassium salt.

### Claim 173

A method of treating or preventing a hepatic disease, disorder, or injury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR1A;
R2 is halogen, hydroxyl, or optionally substituted aliphatic;
R2′ is hydrogen, or R2 and R2′ may optionally be joined to form oxo;
R3 is hydrogen or deuterium;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR4A;
A is phenyl; and
R1A and R4A are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, —CI3, —CHF2, —CHCl2, —CHBr2, —CHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 174 (depends on 173)

The method of claim 173, wherein the hepatic disease, disorder, or injury is fibrosis.

### Claim 175 (depends on 173, 174)

The method of claim 173 or 174, wherein the compound of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 176 (depends on 173, 174, 175)

The method of any one of claims 173-175, wherein the subject is suffering from obesity, non alcoholic fatty liver disease (NAFLD), a metabolic inflammation-mediated disease or disorder, metabolic syndrome, or any combination thereof.

### Claim 177 (depends on 173, 174, 175)

The method of any one of claims 173-175, wherein the pharmaceutically acceptable salt is a potassium salt.

### Claim 178

A method of treating or preventing hepatocyte fibrogenesis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR1A;
R2 is halogen, hydroxyl, or optionally substituted aliphatic;
R2′ is hydrogen, or R2 and R2′ may optionally be joined to form oxo;
R3 is hydrogen or deuterium;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or —OR4A;
A is phenyl; and
R1A and R4A are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, —CI3, —CHF2, —CHCl2, —CHBr2, —CHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 179 (depends on 178)

The method of claim 178, wherein the subject is suffering from obesity, non-alcoholic fatty liver disease (NAFLD), a metabolic inflammation-mediated disease or disorder, metabolic syndrome, or any combination thereof.

### Claim 180 (depends on 179)

The method of claim 179, wherein the NAFLD is non-alcoholic steatohepatitis (NASH).

### Claim 181 (depends on 178, 179, 180)

The method of any one of claims 178-180, wherein the compound of Formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 182 (depends on 178, 179, 180, 181)

The method of any one of claims 178-181, wherein the pharmaceutically acceptable salt is a potassium salt.

### Claim 183 (depends on 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The method of any one of claims 126-182, wherein further comprising an additional therapeutic agent.

### Claim 184 (depends on 183)

The method of claim 183, wherein the additional therapeutic agent is a GLP1 agonist.

### Claim 185 (depends on 184)

The method of claim 184, wherein the GLP1 agonist is exenatide, liraglutide, semaglutide, or dulaglutide.

### Claim 186 (depends on 185)

The method of claim 185, wherein the GLP1 agonist is exenatide.
